The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.
 
Frederick L. Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Celgene; Cellular Biomedicine Group; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Novartis; Sana Biotechnology; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Tanya Siddiqi
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Juno Therapeutics; Pharmacyclics
Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Pharmacyclics/Janssen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Caron Alyce Jacobson
Honoraria - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Consulting or Advisory Role - Abintus Bio; Bluebird Bio; Bristol-Myers Squibb; Celgene; Daiichi Sankyo/UCB Japan; Epizyme; ImmPACT-Bio; Instil Bio; Ipsen; Kite/Gilead; Lonza; Novartis
Research Funding - Kite, a Gilead company; Pfizer
 
Armin Ghobadi
Honoraria - Kite, a Gilead Company
Consulting or Advisory Role - Amgen; Atara Biotherapeutics; Celgene; Kite, a Gilead Company; WUGEN, Inc.
Research Funding - Amgen; Kite, a Gilead Company
 
Sairah Ahmed
Honoraria - Novartis; Seagen
Consulting or Advisory Role - Myeloid Therapeutics; Sanofi; Tessa Therapeutics
Research Funding - Merck (Inst); Seagen (Inst); Tessa Therapeutics (Inst)
 
David Bernard Miklos
Honoraria - fosun Kite Biotechnology; Janssen
Consulting or Advisory Role - Adaptive Biotechnologies; Janssen; Juno/Celgene; Pharmacyclics
Research Funding - Adaptive Biotechnologies; Adicet Bio; Alimera Sciences; Kite, a Gilead company; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim)
 
Miguel-Angel Perales
Stock and Other Ownership Interests - NexImmune
Honoraria - MorphoSys
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Cidara Therapeutics; Incyte; Kite/Gilead; Medigene; Merck; MolMed; Nektar; NexImmune; Novartis; Omeros; Servier/Pfizer; Vor Biopharma
Research Funding - Incyte (Inst); Kite, a Gilead company (Inst); Miltenyi Biotec (Inst); Nektar (Inst); Novartis (Inst)
 
Javier Munoz
Honoraria - Kyowa Hakko Kirin; Seagen
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Fosun Kite; Genentech; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Pfizer; Pharmacyclics; Seagen
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen
 
Brent Logan
Consulting or Advisory Role - Enlivex Therapeutics Ltd
 
Zhen-Huan Hu
Employment - Kite, a Gilead Company
Research Funding - Bristol-Myers Squibb; Kite, a Gilead Company; Novartis
 
Harry H. Miao
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Kanwarjit Singh
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Jina Shah
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Hairong Xu
Employment - Kite, a Gilead Company
Stock and Other Ownership Interests - Gilead Sciences
 
Marcelo C. Pasquini
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Kite, a Gilead Company; Novartis